Clinical Trials Logo

Clinical Trial Summary

The primary hypothesis is that Lactobacillus paracasei ssp. paracasei strain F19 in an infant formula containing FOS/GOS is safe and tolerable for use in infants from 0 to 6 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01625273
Study type Interventional
Source Arla Foods
Contact
Status Completed
Phase N/A
Start date January 2010
Completion date April 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05578716 - Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula N/A
Completed NCT00340665 - Study of Infant Diets on Estrogen Activity and Development
Not yet recruiting NCT06318117 - Reason for Prescribing Rice Infant Formula
Completed NCT05224947 - Gastric Layering and Monitoring II N/A
Completed NCT05097924 - Gastrointestinal Tolerability of a Partially Hydrolyzed Ready-to-feed Infant Formula in Healthy Newborns
Recruiting NCT05992493 - The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infants
Completed NCT03456934 - Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease N/A
Recruiting NCT05868408 - Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants N/A
Completed NCT05295030 - Effects of Breast Milk Simulated Infant Formula N/A